US Officials to Correct Misinformation on Nicotine E-Cigarettes

Dec.13.2022
US Officials to Correct Misinformation on Nicotine E-Cigarettes
US tobacco researchers ask CDC for correct information on e-cigarettes, with health officials correcting misleading public health statements.

Tobacco researchers in the United States have consulted with the Centers for Disease Control and Prevention (CDC). The US Secretary of Health will address some incorrect information released by public health agencies regarding nicotine e-cigarettes.


US Health Secretary Vivek Murthy has recently launched an initiative to reduce the spread of health misinformation in light of the COVID-19 pandemic. As part of this effort, he has advised public health institutions such as the Centers for Disease Control and Prevention (CDC) to stop promoting inaccurate information about electronic cigarettes. For instance, the CDC had disseminated misleading information about the lung injuries caused by e-cigarettes in 2019 (EVALI), and the Health Secretary's report about youth e-cigarette use in 2016 had wrongly claimed that nicotine e-cigarettes were the most commonly used among young people.


The call was made in an editorial published in the Addiction journal. It was co-written by Michael Pesko, a health economist at Georgia State University, along with colleagues from Harvard Medical School, Pennsylvania State University, the Medical University of South Carolina and the University of Michigan. Tom Miller, the former chairman of the Truth Initiative board and Iowa's attorney general, was also a co-author.


The author of the editorial explained that the Center for Disease Control (CDC) named the lung injury of 2019 related to the usage of e-cigarettes as "EVALI" and refused to change the name, which led to widespread attention and misunderstanding from the public and scientific community about the cause of the disease.


It has been reported that the current director of the FDA's Center for Tobacco Products, Brian King, coined the term "EVALI." King is a staunch opponent of nicotine e-cigarettes and was formerly an employee in the smoking and health office at the Centers for Disease Control and Prevention.


The name EVALI has been indirectly responsible for the deaths of 68 people and has sent thousands to hospital, as they were not given a clear warning by public health officials about the risks associated with unregulated electronic cigarettes containing THC oil.


According to the author, all evidence indicates that the illegal tetrahydrocannabinol (THC) e-cigarettes contaminated with vitamin E acetate are the main risk factor for illness, but there is no research indicating any chemicals found in nicotine e-cigarettes. Vitamin E acetate is insoluble in nicotine e-liquid and has never been detected in nicotine e-cigarettes.


The author suggests that despite evidence to the contrary, the Center for Disease Control (CDC) continues to include e-cigarettes in the EVALI designation. This naming convention has had an impact on news reporting and has contributed to a distorted belief among consumers that using nicotine e-cigarettes is risky.


In 2021, the same author officially requested that the Centers for Disease Control and Prevention trace a change in the name "EVALI," removing "e-cigarette" from the name and adding "adult THC.


2FIRSTS will continue to report on this topic, with further updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

InterTabac 2025 Highlights Europe’s Vaping Dilemma: Tighter Regulation, Constrained Innovation
InterTabac 2025 Highlights Europe’s Vaping Dilemma: Tighter Regulation, Constrained Innovation
According to 2Firsts’ on-site observations, the vaping halls at InterTabac 2025 have visibly cooled: fewer exhibitors, a weaker presence from major brands, and scarce stage activations; new product momentum is weak and homogenization has intensified. Tightening regulation and policy uncertainty are squeezing innovation, pushing companies to replicate proven models—overall, a “cautious showcase.”
Sep.19 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Cambodia Enforces Full Ban on E-Cigarettes and Shisha to Protect Youth
Cambodia Enforces Full Ban on E-Cigarettes and Shisha to Protect Youth
Cambodian Prime Minister Hun Manet signs order to strengthen enforcement of e-cigarette and shisha bans, citing health risks and youth usage.
Oct.23 by 2FIRSTS.ai
France plans to impose new taxes on e-liquids, with the vape industry association warning of unemployment risk
France plans to impose new taxes on e-liquids, with the vape industry association warning of unemployment risk
French government proposes tax on e-liquid, sparking concerns over job losses and increased smuggling and underage sales risks.
Oct.16 by 2FIRSTS.ai
2Firsts On-Site at InterTabac: Industry Suppliers Confident About Outlook Despite Stagnant Cigarette Volumes
2Firsts On-Site at InterTabac: Industry Suppliers Confident About Outlook Despite Stagnant Cigarette Volumes
At InterTabac 2025, 2Firsts spoke with traditional tobacco suppliers. Despite stagnant cigarette sales in many regions, they remained optimistic, believing that adapting to market shifts could help them grow in a shrinking sector. Many companies are now moving into emerging categories like nicotine pouches, roll-your-own, and heat-not-burn products, using innovation and infrastructure upgrades to meet changing consumer and regulatory demands.
Sep.22
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris International’s Korea unit has extended the warranty for the “IQOS ILUMA i” heated tobacco series from 12 to 18 months, applying it retroactively to existing purchases, aiming to enhance user experience and market competitiveness.
Oct.15 by 2FIRSTS.ai